I held high hopes for the science and treatments for serious...

First 556 Last

Share
Profile

Follow
Tanybryn

288 Posts.

100

24/04/25

09:15

Post #: 78786447
Share

Originally posted by Footmax: ↑

Agree - this mob is not into positive shareholder relations and never has been - that is despite promised that they would improve that situation.

However, the antiviral sector is crying out for new medicines and maybe, just maybe, BIT225 could be seen by Biotech firms as a chance to do that. personally, I think it is a very long shot though.

I also think that any movement will not provide BIT with any material financial benefit that would allow the company to continue operations, and it will fold in 2025.

It may, however, give shareholders a small return on their investment.

BIT has been poorly managed for many years, and its financial management has been appalling. The day of wine and roses are quickly coming to an end for the BOD - and to the extreme detriment of long suffering shareholders whom I do have genuine sympathy for.

That would be tempered by the question of why many have stayed the journey this long - well after the writing on the wall suggested that BIT is a lost cause.

Expand

I held high hopes for the science and treatments for serious diseases at the beginning

Now 99.4% down, I have nothing to lose and possibly something to gain … even if C14 or MM inadvertently bump into a pharmacy sales person in the supermarket

BIT Price at posting: 0.3¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 556 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $2.654M

Open	High	Low	Value	Volume
0.2¢	0.2¢	0.2¢	$184	92K

Buyers (Bids)

No.	Vol.	Price($)
60	36594676	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	14236347	24

View Market Depth

No.	Vol.	Price($)
60	36594676	0.002
32	65031001	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	14236347	24
0.004	12820969	17
0.005	6684000	5
0.006	1200000	2
0.007	1084188	2

Last trade - 11.37am 27/06/2025 (20 minute delay)

BIT (ASX) Chart

I held high hopes for the science and treatments for serious...

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

I held high hopes for the science and treatments for serious...

Top Stories

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Australia’s gas crisis is here – and dying coal plants aren’t helping

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News